Axovant's Alzheimer's drug fails in late-stage trial, shares plummet

(Reuters) - Axovant Sciences Ltd's drug failed to improve cognitive abilities and daily activities in Alzheimer's patients, in the latest setback to finding a treatment for the memory-robbing disease that affects millions in the United States.